Summary

Help your eligible HR+/HER2– aBC patients achieve
their treatment goals

1L KISQALI + AI increased mOS by >1 year (12.5 months) vs placebo + AI in postmenopausal paients1 – mOS at median 80-month follow-up was 63.9 months with KISQALI + AI vs 51.4 months with AI alone (HR=0.76; 95% CI: 0.63–0.93; p=0.008).1 In an exploratory analysis, 1L KISQALI + fulvestrant was observed to demonstrate significant OS vs fulvestrant + placebo in postmenopausal patients2 – This was an exploratory OS analysis with an extended median follow-up of 71 months: mOS was 67.6 months with 1L KISQALI + fulvestrant vs 51.8 months with fulvestrant alone (HR=0.673; 95% CI: 0.504–0.899).2 In an exploratory analysis, 2L KISQALI + fulvestrant was observed to have a longer mOS in postmenopausal patients* vs placebo + fulvestrant2 – This was an exploratory OS analysis with an extended median follow-up of 71 months: mOS was 37.9 months in the KISQALI + fulvestrant arm vs 33.7 months in the fulvestrant arm (HR=0.80; 95% CI: 0.61–1.05).2

These results were observational in nature; as such, there was no prespecified statistical procedure controlling for type 1 error. Results should be interpreted with caution due to the limitations of exploratory analyses.

*Early relapse or one prior ET for aBC.2

1L, first-line; 2L, second-line; aBC, advanced breast cancer; AI, aromatase inhibitor; CI, confidence interval; ET, endocrine therapy; HER2–, human epidermal growth factor receptor 2-negative; HR, hazard ratio; HR+, hormone receptor-positive; mOS, median overall survival.